scholarly journals Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (12) ◽  
pp. 20198-20212 ◽  
Author(s):  
Xu Jia ◽  
Chandrakumar Shanmugam ◽  
Ravi K. Paluri ◽  
Nirag C. Jhala ◽  
Michael P. Behring ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Loss Of Heterozygosity ◽  
Prognostic Value ◽  
Cellular Localization ◽  
Tumor Stage

scholarly journals Comprehensive Analysis of the Expression, Prognostic Value and Correlations with Immune Infiltration of PBX Family Members in Colorectal Cancer

2021 ◽  
Author(s):  
Yanping Hu ◽  
Yihang Shen
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Interaction Analysis ◽  
Family Members ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
Immune Infiltration ◽  
Colorectal Cancer Patients

Abstract Background: Colorectal cancer is the third commonest cancer and the second leading cause of cancer deaths globally. The Pre-B-cell leukemia transcription factor (PBX) family plays an essential biological role in the growth and development of the organism. PBX genes have been found to be implicated in the tumorigenesis of a variety of human tumors through multiple pathways, but its function in colorectal cancer is unclear. Methods: The expression pattern, prognostic value and relationship with immune infiltration of PBX genes in patients with colorectal cancer were investigated using the Oncomine, GEPIA, Kaplan-Meier Plotter and TIMER databases. In addition, gene mutation and interaction analysis of PBX family members in colorectal cancer patients using cBioPortal and GeneMANIA databases, respectively.Results: We revealed that a significantly lower expression level of PBX1, PBX2 and PBX3 in colorectal cancer tissues than in normal tissues, and the expression levels of PBX1 and PBX2 were significantly correlated with clinical tumor stage. Furthermore, survival analysis showed that high transcript levels of PBX4 were associated with overall survival in colon cancer patients, while low levels of PBX2 predicted improved disease-free survival in rectal cancer patients. In addition, in colon and rectal cancers, PBX proteins were notably associated with infiltration of multiple immune cells, including CD4+ T cells, CD8+ T cells, macrophages, neutrophils, B cells, and dendritic cells.Conclusion: These findings implies that PBX1 and PBX3 are potential targets for precision therapy of colorectal cancer patients and that PBX2 and PBX4 may be new prognostic markers for colorectal cancer patients.

scholarly journals Characterization and clinical evaluation of microsatellite instability and loss of heterozygosity within tumor-related genes in colorectal cancer

2019 ◽  
Author(s):  
Xueyun Huo ◽  
Dandan Feng ◽  
Shuangyue Zhang ◽  
Zhenkun Li ◽  
Xiaohong Li ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Instability ◽  
Loss Of Heterozygosity ◽  
Clinical Features ◽  
Lymphatic Metastasis ◽  
Predictive Value ◽  
Prognostic Value ◽  
Mucinous Carcinoma ◽  
The Relationship ◽  
Very High

Abstract Background: Microsatellite instability (MSI) has been known as a biomarker for better outcome in colorectal cancer (CRC). However, the conclusion is controversy. In addition, MS can also be a useful marker for loss of heterozygosity (LOH) of genes but it has not been well studied yet. Here, aimed to clarify the predictive value of MSI/LOH within tumor-related genes in CRCs, we detected MSI/LOH of MSs in tumor-related genes and the Bethesda (B5) panel and further analyzed the relationship between MSI/LOH and clinical features or outcomes. Results: As expected, the MSI rate of B5 loci were all very high, suggesting that B5 panel criterion is powerful for MSI status determining of CRCs. Interestingly, MSI/LOH of 2 loci in the B5 panel and 12 loci in tumor-related genes were associated with poorer outcome while MSI/LOH of B5 panel was failed to predict outcomes of CRCs. MSI of BAT25, MSI/LOH of BAT26 and MSI of B5 panel showed closer relationship with mucinous carcinoma. In addition, LOH-H of B5 panel associated with more lymphatic metastasis. Conclusions: In summary, MSI/LOH of certain loci or whole panel of B5 were related to the clinical features, and several loci within tumor-related genes showed a prognostic value in outcomes of CRCs.

scholarly journals A New Assay for Measurement of the Liberated Domain I of the Urokinase Receptor in Plasma Improves the Prediction of Survival in Colorectal Cancer

2010 ◽  
Vol 56 (10) ◽  
pp. 1636-1640 ◽  
Author(s):  
Tine Thurison ◽  
Anne F Lomholt ◽  
Morten G Rasch ◽  
Ida K Lund ◽  
Hans J Nielsen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Value ◽  
Proportional Hazards Model ◽  
Tumor Stage ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model ◽  
Urokinase Plasminogen Activator Receptor ◽  
Limit Of Quantification ◽  
Surface Plasmon Resonance Analysis ◽  
Domain I

BACKGROUND The liberated domain I of the urokinase plasminogen activator receptor [uPAR(I)] is a significant prognostic marker in lung and ovarian cancer, although the uPAR(I) concentration is below the limit of quantification (LOQ) in a substantial proportion of patient samples (Lung Cancer 2005;48:349–55; Clin Cancer Res 2008;14:5785–93; APMIS 2009;117:755–61). This study was undertaken to design an immunoassay with improved functional sensitivity for measuring uPAR(I) and to evaluate the prognostic value of uPAR(I) for colorectal cancer (CRC) patients. METHODS Surface plasmon resonance analysis identified 2 monoclonal antibodies, R3 and R20, that simultaneously bind to the liberated uPAR(I) but not to intact uPAR. We used R3 for capture and Eu-labeled R20 for detection in designing a 2-site sandwich time-resolved fluorescence immunoassay (TR-FIA 4) for measuring liberated uPAR(I). TR-FIA 4 was validated for use with citrated plasma. The prognostic value of the uPAR(I) concentration was evaluated in 298 CRC patients. The Cox proportional hazards model was used for the uni- and multivariate survival analyses. RESULTS The LOQ was 0.65 pmol/L. Liberated uPAR(I) was measurable in all patient samples with TR-FIA 4. In the multivariate analysis that included sex, age, tumor stage, tumor localization, and adjuvant treatment, the uPAR(I) concentration measured with TR-FIA 4 (hazard ratio, 1.72; 95% CI, 1.15–2.57; P = 0.009), as well as the concentration of intact soluble uPAR plus the cleaved uPAR fragment containing domains II and III, tumor stage, and age were independent predictors of prognosis. CONCLUSIONS TR-FIA 4 has a functional sensitivity improved 4-fold over that of the previous uPAR(I) assay. The uPAR(I) concentration measured with TR-FIA 4 is an independent predictor of prognosis in CRC patients.

Prognostic Value of Erythrocyte Sedimentation Rate in Patients with Colorectal Cancer

2008 ◽  
Vol 24 (5) ◽  
pp. 351
Author(s):  
Young Ki Kim ◽  
Seong Woo Hong ◽  
Jung Woo Chun ◽  
Yeo Goo Chang ◽  
In Wook Paik ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Erythrocyte Sedimentation Rate ◽  
Sedimentation Rate ◽  
Prognostic Value ◽  
Erythrocyte Sedimentation

scholarly journals Are there sex differences among colorectal cancer patients in treatment and survival? A Swiss cohort study

2021 ◽  
Vol 147 (5) ◽  
pp. 1407-1419
Author(s):  
Manuela Limam ◽  
Katarina Luise Matthes ◽  
Giulia Pestoni ◽  
Eleftheria Michalopoulou ◽  
Leonhard Held ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Regression Models ◽  
Proportional Hazards ◽  
Treatment Decision ◽  
Tumor Stage ◽  
Primary Treatment ◽  
Cox Proportional Hazards ◽  
Men And Women ◽  
Logistic Regression Models ◽  
Comorbidity Index

Abstract Background Colorectal cancer (CRC) is among the three most common incident cancers and causes of cancer death in Switzerland for both men and women. To promote aspects of gender medicine, we examined differences in treatment decision and survival by sex in CRC patients diagnosed 2000 and 2001 in the canton of Zurich, Switzerland. Methods Characteristics assessed of 1076 CRC patients were sex, tumor subsite, age at diagnosis, tumor stage, primary treatment option and comorbidity rated by the Charlson Comorbidity Index (CCI). Missing data for stage and comorbidities were completed using multivariate imputation by chained equations. We estimated the probability of receiving surgery versus another primary treatment using multivariable binomial logistic regression models. Univariable and multivariable Cox proportional hazards regression models were used for survival analysis. Results Females were older at diagnosis and had less comorbidities than men. There was no difference with respect to treatment decisions between men and women. The probability of receiving a primary treatment other than surgery was nearly twice as high in patients with the highest comorbidity index, CCI 2+, compared with patients without comorbidities. This effect was significantly stronger in women than in men (p-interaction = 0.010). Survival decreased with higher CCI, tumor stage and age in all CRC patients. Sex had no impact on survival. Conclusion The probability of receiving any primary treatment and survival were independent of sex. However, female CRC patients with the highest CCI appeared more likely to receive other therapy than surgery compared to their male counterparts.

scholarly journals Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Peter W. Eide ◽  
Seyed H. Moosavi ◽  
Ina A. Eilertsen ◽  
Tuva H. Brunsell ◽  
Jonas Langerud ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
Principal Components ◽  
Prognostic Value ◽  
Tumor Heterogeneity ◽  
Molecular Subtypes ◽  
R Package ◽  
Data Set ◽  
Primary Tumors ◽  
External Data

AbstractGene expression-based subtypes of colorectal cancer have clinical relevance, but the representativeness of primary tumors and the consensus molecular subtypes (CMS) for metastatic cancers is not well known. We investigated the metastatic heterogeneity of CMS. The best approach to subtype translation was delineated by comparisons of transcriptomic profiles from 317 primary tumors and 295 liver metastases, including multi-metastatic samples from 45 patients and 14 primary-metastasis sets. Associations were validated in an external data set (n = 618). Projection of metastases onto principal components of primary tumors showed that metastases were depleted of CMS1-immune/CMS3-metabolic signals, enriched for CMS4-mesenchymal/stromal signals, and heavily influenced by the microenvironment. The tailored CMS classifier (available in an updated version of the R package CMScaller) therefore implemented an approach to regress out the liver tissue background. The majority of classified metastases were either CMS2 or CMS4. Nonetheless, subtype switching and inter-metastatic CMS heterogeneity were frequent and increased with sampling intensity. Poor-prognostic value of CMS1/3 metastases was consistent in the context of intra-patient tumor heterogeneity.

scholarly journals 126P Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab

2020 ◽  
Vol 31 ◽  
pp. S290
Author(s):  
N.I. Nissen ◽  
S. Kehlet ◽  
M.K. Boisen ◽  
M. Liljefors ◽  
C. Jensen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Prognostic Value
Sign in / Sign up

Export Citation Format

Share Document